Vitamin D in colon cancer reshaped the tumor immune environment

Vitamin D in colon cancer may influence more than the cancer cells themselves. In a small randomized trial, a short course of high-dose vitamin D altered both the composition and spatial organization of immune cells inside human colon tumors.

The timescale is one of the most striking parts of the study. The median duration of vitamin D treatment before surgery was only eight days.

The trial enrolled patients with resectable stage I–III colon cancer. Participants were randomly assigned to receive vitamin D3 or placebo. Those in the treatment arm took 50,000 IU of vitamin D3 daily for seven days, followed by 10,000 IU per day until surgery. These were pharmacological doses administered within a monitored clinical trial, not a routine vitamin D supplementation regimen.

Forty-two patients were randomized. Sufficient tumor material for the protocol-specified tissue analysis was available from 24 participants: 11 in the vitamin D group and 13 in the placebo group. Tumor biopsies obtained before treatment were compared with tissue removed during surgery, allowing the researchers to map immune cells within the tumor.

The change was inside the tumor

The blood measurements showed that the intervention worked as intended. At baseline, almost all participants had circulating 25-hydroxyvitamin D levels below 30 ng/mL. After supplementation, the median level reached 59.6 ng/mL in the vitamin D arm, compared with 17.8 ng/mL in the placebo arm.

The more unusual finding was in the tumors themselves.

Vitamin D supplementation was associated with an increase in the density of CD8+ cytotoxic T cells, immune cells capable of recognizing and killing abnormal cells. The increase was particularly evident among CD8+ memory T cells. At the same time, the density of regulatory T cells, which can suppress other immune responses, decreased.

Among patients with paired samples, CD8+ cytotoxic T-cell density increased in 75% of those receiving vitamin D, compared with 30% in the placebo group.

But the researchers did not only count cells. They also asked where those cells were located.

The location of an immune cell can matter almost as much as its identity. A cytotoxic T cell at the edge of a tumor is biologically different from one positioned directly beside a cancer cell.

Spatial analyses showed that after vitamin D supplementation, cytotoxic T cells were distributed more evenly from the invasive edge toward the tumor center. Tumor-centered neighborhood analysis also found a greater representation of CD8+ cytotoxic and memory T cells immediately around cancer cells.

Vitamin D therefore appeared to change not only how many immune cells were present, but also the immune geography of the tumor.

How could vitamin D do this?

Vitamin D signals through the vitamin D receptor, or VDR, a protein that regulates gene activity after binding the active form of the vitamin. VDR is found not only in colon cancer cells but also in immune and stromal cells within the tumor microenvironment.

Spatial transcriptomic analysis provided evidence of altered VDR-related transcriptional activity after supplementation. The researchers also detected changes in signals associated with T-cell recruitment. The study, however, does not establish the complete molecular pathway responsible for the immune-cell redistribution.

VDR itself produced an unexpected result. Its expression varied widely between tumors and decreased overall after treatment. The biology therefore does not fit a simple model in which more vitamin D automatically produces more receptor and a stronger response.

The central limitation of the trial follows directly from what it was designed to measure. This was a biological window-of-opportunity study conducted before surgery. It did not test whether vitamin D shrinks tumors, prevents recurrence, or extends survival.

That distinction matters because the larger phase III SOLARIS trial in metastatic colorectal cancer did not show a statistically significant improvement in progression-free survival from high-dose vitamin D in the overall study population.

The present study was also small. Although 42 patients were randomized, adequate tissue for the main protocol analysis was available from only 24, and some immune analyses involved even fewer specimens. The duration of supplementation and the interval between the final dose and surgery also varied.

The key question addressed here is therefore not whether vitamin D can treat colon cancer. It is whether vitamin D can alter the immune organization of an existing human tumor over a short period of time.

In this experiment, it did. Within days, both the balance of several T-cell populations and their spatial relationship to cancer cells changed. That moves one aspect of vitamin D biology in cancer from cell cultures and animal models into directly mapped human tumor tissue.